LONDON, UK, and MELBOURNE, Australia, July 15, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for QBiotics Group Limited (QBiotics) and is pleased to announce the placement of Sergio Duchini as Non-executive Director.QBiotics is an unlisted public Australian life sciences company that specializes in the discovery and development of novel small molecules to treat complex medical conditions. Its current therapeutic focus is on oncology and wound healing. The…
Internationally recognised leaders will provide expert technical guidance to support Arecor in its mission to develop a game-changing oral delivery of peptides technology platform
Cambridge, UK,14 July 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the formation of its new Scientific Advisory Board of internationally recognised experts in the fields of oral drug delivery and peptide therapeutics.
Arecor is leveraging its significant formulation and product development expertise to develop a…
Aubagne, France; Bratislava, Slovakia/Boston, US/Oxford, UK | July 10, 2025 New partnership to advance cell-based mRNA production Sartorius to support GMP readiness through integrated process development and facility design Expansion planned across Europe and North America Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, and Sensible Biotechnologies, a pioneer in cell-based design and manufacturing of mRNA therapeutics, have signed a Memorandum of Understanding (MoU). The two companies will jointly advance the…
Experienced Life Sciences Ecosystem Super-connector Joins the Innovative Industry Membership Organisation
Cambridge, UK: 10 July 2025
One Nucleus, the Cambridge based not-for-profit membership organisation for life science businesses, is delighted to announce the appointment of Philippa Clark as their new Director of Business Development.
Philippa is a highly experienced professional in the life sciences sector with twenty years’ experience in client development and engagement to support growth. Philippa actively participates in numerous accelerator and mentoring…
London, July 10, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for iOnctura and is pleased to announce the placement of Steven Sciuto as Chief Financial Officer.iOnctura is a clinical-stage precision oncology company combating neglected and hard-to-treat cancers with a pipeline of first-in-class small molecules.Steven Sciuto is a seasoned finance executive with more than 15 years of corporate finance leadership and capital markets experience within…
Read July eNews here 👉 https://shorturl.at/OHhJc
Featuring:
✅ A Sense of Togetherness to Succeed in Tough Times by Tony Jones, CEO, One Nucleus
✅ Unlocking Strategic Procurement in Life Sciences, 18 June 2025 by Alicia Gailliez, Business Development Manager, One Nucleus
✅ Will London, 3 December 2025, be the Genesis of Your Next Step to Success? by Tony Jones, One Nucleus
✅ Targeting the Right Investors at the Right Time with the Right Proposition – How One Nucleus Can Support Members on the Fundraising Trail by Tony Jones, One Nucleus
✅ Bridging the Knowledge Gap: Why Training Your Team on…
London & Copenhagen, July 8, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Biomia and is pleased to announce the placement of Frederick Westhorpe, PhD as Chief Scientific Officer (CSO).Biomia is a preclinical biotech company that uses synthetic biology, biomanufacturing, and AI to discover and optimize nature-inspired medicines. The Company develops novel treatments for CNS disorders like cognitive deficits in mental health, neurodegenerative…
At the forefront of immunotherapy innovation, Creative Biolabs boasts a next-generation custom CAR design and construction platform that allows researchers to create highly specific chimeric antigen receptors for various targets and applications. From streamlining signal domains to selecting best-fit backbones for vectors, their platform is designed for flexibility, precision, and velocity. Creative Biolabs leads in hybrid CAR engineering through the design of multi-functional receptor structures that enhance antigen recognition, modulate activation thresholds, and introduce dual-…
LONDON, UK and BRUSSELS, Belgium - July 3, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed search assignments for Augustine Therapeutics NV (“Augustine”) and is pleased to announce the placements of Carl Bjartmar as Chief Medical Officer (CMO), Virginie Cartage as Chief Financial Officer (CFO), and Rie Schultz Hansen as Chief Scientific Officer (CSO).Augustine Therapeutics is a biotechnology company focused on developing new therapies for neuromuscular,…
Timely access to high-quality peptides is essential in drug discovery, especially for screening, structure-activity relationship (SAR) studies, and early-stage preclinical research. Any delay in peptide synthesis can slow down critical experiments, affect project timelines, and limit the ability to make rapid decisions in lead optimisation.Recognising the critical role of fast, reliable, and risk-free peptide delivery in accelerating the development of new therapies, launched the o2h Peptide Guarantee Programme, designed to deliver peptides in just 2 weeks, to accelerate your discovery…